Andere talen SymBio Pharmaceuticals Limited

Aandelen

4582

JP3383050006

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
172 ^JPY	-1,15%		-1,71%	-30,36%

13/02	SymBio Pharmaceutical's FY2023 inkomsten missen prognose door hoger dan verwacht operationeel verlies	MT
08/02	SymBio Pharmaceuticals Limited geeft winstverwachting voor het boekjaar 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	19/04
SymBio Pharmaceuticals Limited amended terms of the transaction	18/03
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	13/02
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	08/02
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	08/02
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	15/11
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	14/11
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	14/11
SymBio Pharmaceuticals Limited amended terms of the transaction	10/11
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	06-10-23
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	03-08-23
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	03-08-23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	27-04-23
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27-04-23
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	25-04-23
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	24-04-23
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	22-03-23
DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	16-03-23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SymBio Pharmaceuticals Limited

Aandelen

4582

JP3383050006

Andere talen

Filters